PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31827134-0	2019	MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.	erlotinib	44-53	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6	
31827134-5	2019	We also observed expression of constitutively active mutant MAP2K1 (p.K57E) in erlotinib resistant SCC-R cells.	erlotinib	79-88	mitogen-activated protein kinase kinase 1	Homo sapiens	60-66